Aroa Biosurgery (AROA, ASX: ARX) is delighted to announce the appointment of seasoned executive Scott Sherriff as the company’s inaugural Chief Operating Officer (COO).
With over twenty-five years of experience in the pharmaceutical industry, Scott is a senior executive with extensive international experience. He offers strong skills in leadership roles across sales and marketing and managing large cross-functional global teams.
Scott’s current role is Chief Commercial Officer at Douglas Pharmaceuticals, which he has held since returning to New Zealand in 2015 after nearly twenty years working offshore.
Prior to his repatriation, Scott held senior roles at Bayer Pharma Ag and Novartis and is highly adept at understanding consumers, and differing markets, and navigating the complexities involved.
AROA CEO Brian Ward says “We’re pleased that Scott is joining the AROA leadership team in this key new role. With continued revenue growth and over 6 million devices now applied to treating patients worldwide, we have many exciting opportunities ahead. Scott’s experience leading global strategy and operations will be assets during this next phase in AROA’s journey.”
Scott will commence his new role at AROA on 3 July.
